Disinhibition in Frontotemporal Dementia: A Different Chemistry, A Thinner Evidence Base
A family expects the same confident pharmacology that guides Alzheimer's care. Frontotemporal dementia runs on a different neurotransmitter deficit entirely, and the evidence behind treating it is real but genuinely much thinner than what they're used to hearing about.
Patricia L., 61, was a corporate attorney known for exacting professional judgment before symptoms began quietly reshaping her personality nearly three years ago; she made partner at thirty-four and negotiated mergers for a living, a career her husband describes as impossible to imagine her ever losing the sharpness for. Her husband first noticed it as uncharacteristic bluntness with colleagues and strangers alike; it has since progressed to open disinhibition — commenting loudly on strangers' appearance in public, eating other diners' food off their plates at restaurants without apparent awareness this is unusual, and a new, marked preference for sweets that has driven an eighteen-pound weight gain in under a year. Formal evaluation, including MRI showing frontal and anterior temporal atrophy, confirmed behavioral-variant frontotemporal dementia eight months ago.
Her husband, who spent the months before diagnosis reading everything he could about dementia care, arrives today expecting the same kind of confident pharmacologic guidance he's encountered describing Alzheimer's disease — a first-line drug, a clear evidence base, a defined next step. What he's about to hear is different in a way that matters: behavioral-variant FTD's disinhibition and appetite changes are thought to reflect predominantly serotonergic, not cholinergic, deficits, a genuinely distinct neurochemistry from Alzheimer's disease. That distinction cuts two ways at once — it means the drugs that anchor Alzheimer's care are the wrong tool here and may even worsen things, but it also means the alternative, SSRIs, rests on a trial literature that is real, mechanistically motivated, and considerably thinner than what he has come to expect.
In the behavioral neurology clinic
I want to start by naming something that will actually help you make sense of everything else: FTD's disinhibition and appetite changes are thought to come mostly from a loss of serotonergic neurons, not the cholinergic loss that drives Alzheimer's disease. That's why donepezil and the other Alzheimer's drugs aren't the answer here — there's actually some evidence they can make bvFTD's behavioral symptoms worse rather than better, the opposite of what you'd expect from everything you've read.
Given that mechanism, an SSRI like citalopram is the more logical target, and a small open-label trial by Herrmann and colleagues, published in the American Journal of Geriatric Psychiatry in 2012, found real reductions in agitation and irritability scores on the Neuropsychiatric Inventory in FTD patients treated with citalopram.
I want to be direct with the family about how much thinner this evidence is before we go further. The trial I'd point to as a caution is Deakin and colleagues' placebo-controlled trial of paroxetine, a different SSRI, in FTD — published in Psychopharmacology in 2004 — which found no significant behavioral benefit over placebo, and some patients showed measurable cognitive worsening on paroxetine specifically.
I'm not saying don't try citalopram — the mechanistic argument for serotonergic-targeted treatment here is real. I'm saying we shouldn't let the AD-level confidence Patricia's husband is expecting carry over to a trial literature this small and this mixed within its own drug class.
I'd still offer citalopram, framed exactly the way you just put it — a reasonable, low-toxicity, mechanistically-motivated trial, not an established therapy. The realistic alternative some clinicians reach for when behavioral symptoms in FTD escalate is an antipsychotic, and we don't have good dementia-population safety data for that class either.
Given that comparison, a cautious SSRI trial with honest framing about the evidence gap still seems like the right offer today, as long as the family hears the caveat as clearly as the mechanism.
Agreed: a cautious trial of citalopram started at a low dose, framed explicitly to the family as a low-confidence, mechanistically-motivated trial rather than an established therapy, with reassessment of NPI-rated behavioral symptoms at six weeks.
Not agreed: how much of the mechanistic reasoning versus the evidence-gap caution to lead with in future family conversations as her disease progresses. The neurologist believes leading with the distinct-mechanism explanation helps families understand FTD on its own terms; the pharmacologist worries that framing, however accurate, risks implying more confidence in the SSRI's benefit than the trial literature actually supports.